THB Asset Management purchased a new position in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,572 shares of the biotechnology company’s stock, valued at approximately $341,000.

Several other institutional investors and hedge funds have also made changes to their positions in ENTA. Pearl River Capital LLC increased its stake in shares of Enanta Pharmaceuticals by 174.5% during the 1st quarter. Pearl River Capital LLC now owns 280 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 178 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 64.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 634 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 249 shares during the last quarter. Financial Gravity Wealth Inc. acquired a new position in shares of Enanta Pharmaceuticals during the 1st quarter worth $49,000. Bank of Montreal Can increased its stake in shares of Enanta Pharmaceuticals by 33.0% during the 4th quarter. Bank of Montreal Can now owns 870 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 216 shares during the last quarter. Finally, South Dakota Investment Council acquired a new position in shares of Enanta Pharmaceuticals during the 1st quarter worth $76,000. Institutional investors own 89.64% of the company’s stock.

NASDAQ:ENTA opened at $90.47 on Friday. Enanta Pharmaceuticals Inc has a 1 year low of $64.08 and a 1 year high of $127.77. The firm has a market capitalization of $1.80 billion, a P/E ratio of 26.00 and a beta of 1.30.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Tuesday, May 7th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.29. Enanta Pharmaceuticals had a net margin of 33.28% and a return on equity of 19.25%. The business had revenue of $39.60 million for the quarter, compared to analyst estimates of $40.92 million. During the same period last year, the business posted $0.61 EPS. Enanta Pharmaceuticals’s revenue was down 10.0% compared to the same quarter last year. Equities analysts anticipate that Enanta Pharmaceuticals Inc will post 1.9 earnings per share for the current fiscal year.

ENTA has been the topic of a number of research analyst reports. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 9th. Berenberg Bank upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the company from $80.00 to $120.00 in a research note on Tuesday, April 23rd. Wolfe Research initiated coverage on shares of Enanta Pharmaceuticals in a research note on Friday, May 24th. They issued an “outperform” rating and a $117.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $99.00 target price on the stock in a research note on Friday, May 10th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Enanta Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $114.83.

In related news, Director George Golumbeski sold 9,280 shares of the firm’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $103.65, for a total value of $961,872.00. Following the transaction, the director now directly owns 9,280 shares in the company, valued at approximately $961,872. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bruce L. A. Carter sold 1,546 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $99.16, for a total transaction of $153,301.36. Following the completion of the sale, the director now owns 1,546 shares in the company, valued at $153,301.36. The disclosure for this sale can be found here. Company insiders own 11.35% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “3,572 Shares in Enanta Pharmaceuticals Inc (ENTA) Acquired by THB Asset Management” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.watchlistnews.com/3572-shares-in-enanta-pharmaceuticals-inc-enta-acquired-by-thb-asset-management/3029400.html.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: Street Name

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.